Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.

Published

Journal Article

Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported previously that alterations in the intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT. Because intestinal bacteria are potent modulators of systemic immune responses, including antitumor effects, we hypothesized that components of the intestinal flora could be associated with relapse after allo-HCT. Methods The intestinal microbiota of 541 patients admitted for allo-HCT was profiled by means of 16S ribosomal sequencing of prospectively collected stool samples. We examined the relationship between abundance of microbiota species or groups of related species and relapse/progression of disease during 2 years of follow-up time after allo-HCT by using cause-specific proportional hazards in a retrospective discovery-validation cohort study. Results Higher abundance of a bacterial group composed mostly of Eubacterium limosum in the validation set was associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-fold increase in abundance; 95% CI, 0.71 to 0.95; P = .009). When the patients were categorized according to presence or absence of this bacterial group, presence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87; P = .01). The 2-year cumulative incidences of relapse/progression among patients with and without this group of bacteria were 19.8% and 33.8%, respectively. These associations remained significant in multivariable models and were strongest among recipients of T-cell-replete allografts. Conclusion We found associations between the abundance of a group of bacteria in the intestinal flora and relapse/progression of disease after allo-HCT. These might serve as potential biomarkers or therapeutic targets to prevent relapse and improve survival after allo-HCT.

Full Text

Duke Authors

Cited Authors

  • Peled, JU; Devlin, SM; Staffas, A; Lumish, M; Khanin, R; Littmann, ER; Ling, L; Kosuri, S; Maloy, M; Slingerland, JB; Ahr, KF; Porosnicu Rodriguez, KA; Shono, Y; Slingerland, AE; Docampo, MD; Sung, AD; Weber, D; Alousi, AM; Gyurkocza, B; Ponce, DM; Barker, JN; Perales, M-A; Giralt, SA; Taur, Y; Pamer, EG; Jenq, RR; van den Brink, MRM

Published Date

  • May 20, 2017

Published In

Volume / Issue

  • 35 / 15

Start / End Page

  • 1650 - 1659

PubMed ID

  • 28296584

Pubmed Central ID

  • 28296584

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.70.3348

Language

  • eng

Conference Location

  • United States